CN109661391A - S1p1激动剂及其应用 - Google Patents

S1p1激动剂及其应用 Download PDF

Info

Publication number
CN109661391A
CN109661391A CN201780044927.7A CN201780044927A CN109661391A CN 109661391 A CN109661391 A CN 109661391A CN 201780044927 A CN201780044927 A CN 201780044927A CN 109661391 A CN109661391 A CN 109661391A
Authority
CN
China
Prior art keywords
compound
alkyl
pharmaceutically acceptable
acceptable salt
reaction solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780044927.7A
Other languages
English (en)
Other versions
CN109661391B (zh
Inventor
吴凌云
张鹏
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN109661391A publication Critical patent/CN109661391A/zh
Application granted granted Critical
Publication of CN109661391B publication Critical patent/CN109661391B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

本发明涉及一系列三环类化合物及其作为1‑磷酸鞘氨醇1亚型(S1P1)的受体激动剂的应用，具体涉及式(Ⅱ)所示化合物、其互变异构体或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (44)

  1. PCT国内申请，权利要求书已公开。
CN201780044927.7A 2016-07-22 2017-07-21 S1p1激动剂及其应用 Active CN109661391B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610583286X 2016-07-22
CN201610583286 2016-07-22
PCT/CN2017/093808 WO2018014862A1 (zh) 2016-07-22 2017-07-21 S1p1激动剂及其应用

Publications (2)

Publication Number Publication Date
CN109661391A true CN109661391A (zh) 2019-04-19
CN109661391B CN109661391B (zh) 2022-04-19

Family

ID=60991955

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780044927.7A Active CN109661391B (zh) 2016-07-22 2017-07-21 S1p1激动剂及其应用

Country Status (11)

Country Link
US (1) US11192886B2 (zh)
EP (1) EP3492465B1 (zh)
JP (1) JP6883882B2 (zh)
KR (1) KR102481328B1 (zh)
CN (1) CN109661391B (zh)
BR (1) BR112019001153A2 (zh)
CA (1) CA3034796A1 (zh)
ES (1) ES2877686T3 (zh)
RU (1) RU2754845C2 (zh)
WO (1) WO2018014862A1 (zh)
ZA (1) ZA201901089B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3026074A1 (en) 2016-06-01 2017-12-07 M3 Biotechnology, Inc. N-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide compounds and their use to treat neurodegenerative diseases
RU2020127083A (ru) * 2018-01-18 2022-02-18 Медшайн Дискавери Инк. Кристаллическая и солевая формы трициклического соединения и способ их получения
KR102333564B1 (ko) * 2019-11-28 2021-12-01 동방에프티엘(주) 광학 활성 다이아민 유도체 및 티아졸 유도체의 생산을 위한 새로운 합성경로

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101622234A (zh) * 2007-03-06 2010-01-06 诺瓦提斯公司 适于治疗炎性或变应性病症的二环有机化合物
CN102099333A (zh) * 2008-01-10 2011-06-15 阿勒根公司 具有1-磷酸鞘氨醇(s1p)受体拮抗剂生物学活性的6-取代吲哚-3-羧酸酰胺化合物
CN102762100A (zh) * 2009-11-13 2012-10-31 瑞塞普托斯公司 选择性的1-磷酸鞘氨醇受体调节剂及手性合成方法
CN103298807A (zh) * 2010-11-03 2013-09-11 百时美施贵宝公司 作为用于治疗自身免疫性疾病和血管疾病的s1p1激动剂的杂环化合物
CN103380112A (zh) * 2010-11-24 2013-10-30 阿勒根公司 作为s1p受体调节剂的吲哚衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2701B1 (en) * 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
EP2210890A1 (en) * 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
WO2011005290A1 (en) * 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
CA2780433C (en) * 2009-11-13 2018-01-02 Receptos, Inc. Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
JP2013514287A (ja) * 2009-12-17 2013-04-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング スフィンゴシンキナーゼの阻害薬
CN103261157B (zh) * 2010-12-14 2015-12-09 先正达参股股份有限公司 strigolactam衍生物及其作为植物生长调节剂的用途
WO2012158550A2 (en) 2011-05-13 2012-11-22 Receptos, Inc. Selective heterocyclic sphingosine 1 phosphate receptor modulators
GB201121803D0 (en) * 2011-12-16 2012-02-01 Syngenta Participations Ag Plant growth regulating compounds
ES2698359T3 (es) * 2013-02-20 2019-02-04 Lg Chemical Ltd Agonistas del receptor de la esfingosina-1-fosfato, métodos para preparar los mismos y composiciones farmacéuticas que los contienen como agentes activos

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101622234A (zh) * 2007-03-06 2010-01-06 诺瓦提斯公司 适于治疗炎性或变应性病症的二环有机化合物
CN102099333A (zh) * 2008-01-10 2011-06-15 阿勒根公司 具有1-磷酸鞘氨醇(s1p)受体拮抗剂生物学活性的6-取代吲哚-3-羧酸酰胺化合物
CN102762100A (zh) * 2009-11-13 2012-10-31 瑞塞普托斯公司 选择性的1-磷酸鞘氨醇受体调节剂及手性合成方法
CN103298807A (zh) * 2010-11-03 2013-09-11 百时美施贵宝公司 作为用于治疗自身免疫性疾病和血管疾病的s1p1激动剂的杂环化合物
CN103380112A (zh) * 2010-11-24 2013-10-30 阿勒根公司 作为s1p受体调节剂的吲哚衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
田育林 等: "选择性鞘胺醇-1-磷酸受体1激动剂研究进展", 《药学学报》 *

Also Published As

Publication number Publication date
ES2877686T3 (es) 2021-11-17
WO2018014862A1 (zh) 2018-01-25
JP2019522059A (ja) 2019-08-08
ZA201901089B (en) 2022-04-28
RU2019104953A3 (zh) 2020-08-24
JP6883882B2 (ja) 2021-06-09
CA3034796A1 (en) 2018-01-25
CN109661391B (zh) 2022-04-19
EP3492465A1 (en) 2019-06-05
KR102481328B1 (ko) 2022-12-26
US11192886B2 (en) 2021-12-07
KR20190029729A (ko) 2019-03-20
BR112019001153A2 (pt) 2019-04-30
EP3492465B1 (en) 2021-03-24
RU2019104953A (ru) 2020-08-24
US20210300908A1 (en) 2021-09-30
EP3492465A4 (en) 2020-03-04
RU2754845C2 (ru) 2021-09-08

Similar Documents

Publication Publication Date Title
CN111153901B (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
CN107849013B (zh) 作为dub抑制剂用于治疗癌症的氰基吡咯烷类
EP3538525B1 (en) 3-substituted propionic acids as alpha v integrin inhibitors
CN105683188B (zh) 作为fgfr4抑制剂的稠环二环吡啶基衍生物
CN106459009B (zh) 丙肝病毒抑制剂及其制药用途
KR20180048635A (ko) Kit 및 pdgfr에 관련된 장애를 치료하는데 유용한 조성물
WO2021043322A1 (zh) 氮杂环庚烷并嘧啶类衍生物及其医药用途
WO2018133829A1 (zh) 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
CN111683928B (zh) 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物
CN111344290A (zh) 作为Wee1抑制剂的大环类化合物及其应用
CN108884103B (zh) 作为免疫调节剂的三并环化合物
JP7123956B2 (ja) スピロ化合物およびその使用
IL267299B (en) cdk4/6 inhibitor
CN108602757B (zh) 地佐辛类似物
CN105085478B (zh) 异喹啉磺胺衍生物及其药物组合物和制药用途
CN109661391A (zh) S1p1激动剂及其应用
CN110023286A (zh) 作为ccr2/ccr5受体拮抗剂的联苯化合物
WO2022194269A1 (zh) 新型egfr降解剂
CN107709323A (zh) 羟基嘌呤类化合物及其应用
CN111315750B (zh) 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物
CN108135175A (zh) 双环化合物及其用于抑制suv39h2的用途
CN109071469A (zh) 三环类化合物及其应用
CN112574208B (zh) 取代的稠合三环衍生物及其组合物及用途
CN107614501A (zh) 羟基嘌呤类化合物及其应用
TWI690526B (zh) 羥基嘌呤類化合物及其應用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40001048

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210908

Address after: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant after: Nanjing Mingde New Drug Development Co.,Ltd.

Address before: 050035 Innovation Building, 315 Changjiang Avenue, Shijiazhuang High-tech Zone, Hebei Province, 3rd Floor

Applicant before: Shijiazhuang Zhikang Hongren New Drug Development Co.,Ltd.

GR01 Patent grant
GR01 Patent grant